<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01520831</url>
  </required_header>
  <id_info>
    <org_study_id>BIASP-1086</org_study_id>
    <nct_id>NCT01520831</nct_id>
  </id_info>
  <brief_title>Comparison of Biphasic Insulin Aspart (30, 50 and 70) and Insulin Aspart in Healthy Subjects</brief_title>
  <official_title>A Randomised, Four-period Cross-over Trial in Healthy Subjects, Investigating the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, Biphasic Insulin Aspart 50, Biphasic Insulin Aspart 70 and Soluble Insulin Aspart</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to demonstrate a difference
      between the pharmacodynamics and pharmacokinetics of biphasic insulin aspart 30, biphasic
      insulin aspart 50, biphasic insulin aspart 70 and insulin aspart in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 1999</start_date>
  <completion_date type="Actual">May 2000</completion_date>
  <primary_completion_date type="Actual">May 2000</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the GIR (Glucose Infusion Rate) profile (AUC GIR) in the interval 0-120 minutes</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum GIR value</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum GIR value</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the GIR profile</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax, maximum insulin aspart concentration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the insulin aspart concentration curve</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax, the time to maximum insulin aspart concentration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½, terminal half-life</measure>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Diabetes</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BIAsp 30</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BIAsp 50</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BIAsp 70</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin aspart</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biphasic insulin aspart 30</intervention_name>
    <description>One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days</description>
    <arm_group_label>BIAsp 30</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biphasic insulin aspart 50</intervention_name>
    <description>One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days</description>
    <arm_group_label>BIAsp 50</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biphasic insulin aspart 70</intervention_name>
    <description>One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days</description>
    <arm_group_label>BIAsp 70</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin aspart</intervention_name>
    <description>One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days</description>
    <arm_group_label>Insulin aspart</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index between 18 and 28 kg/m^2 inclusive

          -  HbA1c within the normal laboratory range

          -  Non smoker for at least three months

          -  Females of childbearing potential using acceptable methods of contraception, including
             tubal ligation, an intrauterine device (IUD) , the oral contraceptive pill or barrier
             methods

        Exclusion Criteria:

          -  Subjects who have received any investigational drug in the 3 months prior to the start
             of dosing

          -  Any disease requiring regular use of non topical prescription medicines

          -  Any serious systemic infectious disease that occurred in the 4 weeks prior to the
             first dose of test drug

          -  Any intercurrent illness or endocrine disorders that may affect blood glucose

          -  Subject with a history of drug or alcohol dependence

          -  Subject with a first degree relative with diabetes mellitus

          -  Subject with a history of clinically relevant allergic reactions to medical products

          -  Subjects who have donated any blood or plasma in the past 3 month preceding screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Heise T, Kapitza C, Jacobsen LV, Brøndsted L, Heinemann L. Pharmacokinetic and pharmacodynamic differences between premixed suspensions of insulin aspart: biphasic insulin aspart 30, 50 and 70. Diabetologia 2005; 48 (Suppl. 1): A301</citation>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2012</study_first_submitted>
  <study_first_submitted_qc>January 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2012</study_first_posted>
  <last_update_submitted>January 3, 2017</last_update_submitted>
  <last_update_submitted_qc>January 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Biphasic Insulins</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

